Hamza Celik
@hmzacelik.bsky.social
Scientist interested in hematological malignancies. Associate Director, Incyte.
Reposted by Hamza Celik
New in NatureGenetics! 🧠
We illustrated the cover submission for this paper on epigenetic editing of memory expression, a beautiful take on molecular memory. Congrats to all authors!
@graeffjohannes.bsky.social
@dmcoda.bsky.social
We illustrated the cover submission for this paper on epigenetic editing of memory expression, a beautiful take on molecular memory. Congrats to all authors!
@graeffjohannes.bsky.social
@dmcoda.bsky.social
Huge congrats to all authors and thank you @drawimpacts.bsky.social for the cover art illustrating how epigenetic modifications act as molecular memory aids!
October 29, 2025 at 6:18 PM
New in NatureGenetics! 🧠
We illustrated the cover submission for this paper on epigenetic editing of memory expression, a beautiful take on molecular memory. Congrats to all authors!
@graeffjohannes.bsky.social
@dmcoda.bsky.social
We illustrated the cover submission for this paper on epigenetic editing of memory expression, a beautiful take on molecular memory. Congrats to all authors!
@graeffjohannes.bsky.social
@dmcoda.bsky.social
Reposted by Hamza Celik
We are hiring 😀
Postdoctoral position – Stem cells, Cancer, and Aging
We study cell fate decision and lineage specification in hematopoietic stem and multipotent progenitor populations to modulate lineage output for therapeutic purpose in diseases and aging contexts.
Postdoctoral position – Stem cells, Cancer, and Aging
We study cell fate decision and lineage specification in hematopoietic stem and multipotent progenitor populations to modulate lineage output for therapeutic purpose in diseases and aging contexts.
January 12, 2025 at 12:30 AM
We are hiring 😀
Postdoctoral position – Stem cells, Cancer, and Aging
We study cell fate decision and lineage specification in hematopoietic stem and multipotent progenitor populations to modulate lineage output for therapeutic purpose in diseases and aging contexts.
Postdoctoral position – Stem cells, Cancer, and Aging
We study cell fate decision and lineage specification in hematopoietic stem and multipotent progenitor populations to modulate lineage output for therapeutic purpose in diseases and aging contexts.
Reposted by Hamza Celik
Delighted to share our #hematology review article on mutant calreticulin in #MPN
Congrats to co-authors Drs. Mifra Faiz, Merle Riedemann & Jonas Jutzi. We hope it’s a useful resource, link below! @stanforddeptmed.bsky.social
link.springer.com/article/10.1...
Congrats to co-authors Drs. Mifra Faiz, Merle Riedemann & Jonas Jutzi. We hope it’s a useful resource, link below! @stanforddeptmed.bsky.social
link.springer.com/article/10.1...
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications - Current Hematologic Malignancy Reports
Purpose of Review More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MPN), advances in the understanding of CALR-mutant MPN continu...
link.springer.com
January 10, 2025 at 3:29 PM
Delighted to share our #hematology review article on mutant calreticulin in #MPN
Congrats to co-authors Drs. Mifra Faiz, Merle Riedemann & Jonas Jutzi. We hope it’s a useful resource, link below! @stanforddeptmed.bsky.social
link.springer.com/article/10.1...
Congrats to co-authors Drs. Mifra Faiz, Merle Riedemann & Jonas Jutzi. We hope it’s a useful resource, link below! @stanforddeptmed.bsky.social
link.springer.com/article/10.1...
Reposted by Hamza Celik
🎉 Happy New Year from #DrawImpacts Studio! 🎨
We’re thrilled to kick off 2025 with exciting news: our first cover of the year has been selected for #CellStemCell 's first issue of 2025!! To another year of impactful collaborations, science, and creativity—we can’t wait to see what this year brings! 🌟
We’re thrilled to kick off 2025 with exciting news: our first cover of the year has been selected for #CellStemCell 's first issue of 2025!! To another year of impactful collaborations, science, and creativity—we can’t wait to see what this year brings! 🌟
January 2, 2025 at 8:06 PM
🎉 Happy New Year from #DrawImpacts Studio! 🎨
We’re thrilled to kick off 2025 with exciting news: our first cover of the year has been selected for #CellStemCell 's first issue of 2025!! To another year of impactful collaborations, science, and creativity—we can’t wait to see what this year brings! 🌟
We’re thrilled to kick off 2025 with exciting news: our first cover of the year has been selected for #CellStemCell 's first issue of 2025!! To another year of impactful collaborations, science, and creativity—we can’t wait to see what this year brings! 🌟
Reposted by Hamza Celik
A nice review in @bloodjournal.bsky.social of all things menin in AML!
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
December 27, 2024 at 5:51 PM
A nice review in @bloodjournal.bsky.social of all things menin in AML!
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
Reposted by Hamza Celik
Will definitely work with Emma👇
Hi, I’m Emma Vidal, founder of #DrawImpacts, a creative agency specializing in striking cover art for leading journals, scientific figures, logos, slides & web design tailored to the scientific community
We’re new here and excited to connect! Let’s make an impact together!✨🚀 #SciArt
drawimpacts.com
We’re new here and excited to connect! Let’s make an impact together!✨🚀 #SciArt
drawimpacts.com
December 7, 2024 at 5:42 PM
Will definitely work with Emma👇
Reposted by Hamza Celik
Hey all you #ASH24 people.
You need to look at this new paper in @naturemethods.bsky.social by Heme extraordinaires Grant Rowe and the Bluesky-less #HojunLi.
A paper that looks at Blood & Time from @bloodandtime.bsky.social himself!
#scRNAseq
#bioinformatics
🧬 💻
www.nature.com/articles/s41...
You need to look at this new paper in @naturemethods.bsky.social by Heme extraordinaires Grant Rowe and the Bluesky-less #HojunLi.
A paper that looks at Blood & Time from @bloodandtime.bsky.social himself!
#scRNAseq
#bioinformatics
🧬 💻
www.nature.com/articles/s41...
The dynamics of hematopoiesis over the human lifespan - Nature Methods
This Resource presents an atlas classifying the age-related changes in human hematopoietic stem and progenitor cells from gestation through aging.
www.nature.com
December 8, 2024 at 12:53 PM
Hey all you #ASH24 people.
You need to look at this new paper in @naturemethods.bsky.social by Heme extraordinaires Grant Rowe and the Bluesky-less #HojunLi.
A paper that looks at Blood & Time from @bloodandtime.bsky.social himself!
#scRNAseq
#bioinformatics
🧬 💻
www.nature.com/articles/s41...
You need to look at this new paper in @naturemethods.bsky.social by Heme extraordinaires Grant Rowe and the Bluesky-less #HojunLi.
A paper that looks at Blood & Time from @bloodandtime.bsky.social himself!
#scRNAseq
#bioinformatics
🧬 💻
www.nature.com/articles/s41...
Reposted by Hamza Celik
What does the circulating proteome teach us about common heart diseases?
Thrilled to share our analysis identifying new biomarkers, drug targets, and prediction models for these conditions.
Mentored (supremely) by @mchonig.bsky.social and @pnatarajanmd.bsky.social nature.com/articles/s44... (1/x)
Thrilled to share our analysis identifying new biomarkers, drug targets, and prediction models for these conditions.
Mentored (supremely) by @mchonig.bsky.social and @pnatarajanmd.bsky.social nature.com/articles/s44... (1/x)
November 21, 2024 at 11:16 AM
What does the circulating proteome teach us about common heart diseases?
Thrilled to share our analysis identifying new biomarkers, drug targets, and prediction models for these conditions.
Mentored (supremely) by @mchonig.bsky.social and @pnatarajanmd.bsky.social nature.com/articles/s44... (1/x)
Thrilled to share our analysis identifying new biomarkers, drug targets, and prediction models for these conditions.
Mentored (supremely) by @mchonig.bsky.social and @pnatarajanmd.bsky.social nature.com/articles/s44... (1/x)
Reposted by Hamza Celik
Congrats to all involved in this study of a monoclonal antibody targeting mutant CALR in #MPN, first presented at #ASH23, this mAb is now in a phase 1 multicenter clinical trial, open at Stanford #Hematology @stanforddeptmed.bsky.social @bloodjournal.bsky.social
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN
Key PointsWe describe the characterization of INCA033989, a monoclonal antibody that potently and selectively targets mutCALR-positive MPN cells.Data show
ashpublications.org
November 30, 2024 at 6:58 PM
Congrats to all involved in this study of a monoclonal antibody targeting mutant CALR in #MPN, first presented at #ASH23, this mAb is now in a phase 1 multicenter clinical trial, open at Stanford #Hematology @stanforddeptmed.bsky.social @bloodjournal.bsky.social
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
Reposted by Hamza Celik
Congrats to Dr. Jason Gotlib on opening a JAK2V617F selective inhibitor trial at Stanford #Hematology in record time! This is a new class of #JAK2 inhibitor, phase 1 trial for patients with myelofibrosis & JAK2V617F is open & recruiting! @stanforddeptmed.bsky.social
med.stanford.edu/cancer/about...
med.stanford.edu/cancer/about...
Fast-track activation accelerates clinical trial for blood cancer treatment
A clinical trial investigating a promising blood cancer therapy treated its first patient in August 2024 after receiving fast-track activation from the Stanford Cancer Institute in March 2024.
med.stanford.edu
November 29, 2024 at 5:10 PM
Congrats to Dr. Jason Gotlib on opening a JAK2V617F selective inhibitor trial at Stanford #Hematology in record time! This is a new class of #JAK2 inhibitor, phase 1 trial for patients with myelofibrosis & JAK2V617F is open & recruiting! @stanforddeptmed.bsky.social
med.stanford.edu/cancer/about...
med.stanford.edu/cancer/about...
Reposted by Hamza Celik
Excited for #ASH24 & thrilled that *3* brilliant folks from the team have oral presentations, travel awards and 2/3 nominated for **best of ASH**!! @imm.ox.ac.uk @ox.ac.uk @cancerresearchuk.org @ludwigcancer.bsky.social
November 29, 2024 at 10:52 PM
Excited for #ASH24 & thrilled that *3* brilliant folks from the team have oral presentations, travel awards and 2/3 nominated for **best of ASH**!! @imm.ox.ac.uk @ox.ac.uk @cancerresearchuk.org @ludwigcancer.bsky.social
Reposted by Hamza Celik
very cool paper by @mpndoc.bsky.social et al looking at RSK1 as a therapeutic target in FLT3-ITD AML!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
November 29, 2024 at 4:04 PM
very cool paper by @mpndoc.bsky.social et al looking at RSK1 as a therapeutic target in FLT3-ITD AML!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Hamza Celik
Look who's here
@pnas.org ✔️
@science.org ✔️
@naturecellbiology.bsky.social ✔️
@natrevgenet.bsky.social ✔️
@naturebiotech.bsky.social ✔️
@naturemicrobiol.bsky.social ✔️
@naturechemistry.bsky.social ✔️
@genesdev.bsky.social ✔️
@cellchembiol.bsky.social ✔️
@genomeresearch.bsky.social ✔️
@jcellbiol.bsky.social ✔️
@pnas.org ✔️
@science.org ✔️
@naturecellbiology.bsky.social ✔️
@natrevgenet.bsky.social ✔️
@naturebiotech.bsky.social ✔️
@naturemicrobiol.bsky.social ✔️
@naturechemistry.bsky.social ✔️
@genesdev.bsky.social ✔️
@cellchembiol.bsky.social ✔️
@genomeresearch.bsky.social ✔️
@jcellbiol.bsky.social ✔️
November 25, 2024 at 1:47 PM
Look who's here
@pnas.org ✔️
@science.org ✔️
@naturecellbiology.bsky.social ✔️
@natrevgenet.bsky.social ✔️
@naturebiotech.bsky.social ✔️
@naturemicrobiol.bsky.social ✔️
@naturechemistry.bsky.social ✔️
@genesdev.bsky.social ✔️
@cellchembiol.bsky.social ✔️
@genomeresearch.bsky.social ✔️
@jcellbiol.bsky.social ✔️
@pnas.org ✔️
@science.org ✔️
@naturecellbiology.bsky.social ✔️
@natrevgenet.bsky.social ✔️
@naturebiotech.bsky.social ✔️
@naturemicrobiol.bsky.social ✔️
@naturechemistry.bsky.social ✔️
@genesdev.bsky.social ✔️
@cellchembiol.bsky.social ✔️
@genomeresearch.bsky.social ✔️
@jcellbiol.bsky.social ✔️
Reposted by Hamza Celik
Are neutrophils "good" or "bad"?
Rana Herro reviews the current literature here: rdcu.be/d0Rt7
Rana Herro reviews the current literature here: rdcu.be/d0Rt7
The diverse roles of neutrophils from protection to pathogenesis
Nature Immunology - In this Review, Herro and Grimes summarize the most recent key findings surrounding protective versus pathogenic functions of neutrophils, elaborating on phenotype-specific...
rdcu.be
November 20, 2024 at 7:14 PM
Are neutrophils "good" or "bad"?
Rana Herro reviews the current literature here: rdcu.be/d0Rt7
Rana Herro reviews the current literature here: rdcu.be/d0Rt7
Reposted by Hamza Celik
Hi, I’m Emma Vidal, founder of #DrawImpacts, a creative agency specializing in striking cover art for leading journals, scientific figures, logos, slides & web design tailored to the scientific community
We’re new here and excited to connect! Let’s make an impact together!✨🚀 #SciArt
drawimpacts.com
We’re new here and excited to connect! Let’s make an impact together!✨🚀 #SciArt
drawimpacts.com
November 19, 2024 at 8:54 PM
Hi, I’m Emma Vidal, founder of #DrawImpacts, a creative agency specializing in striking cover art for leading journals, scientific figures, logos, slides & web design tailored to the scientific community
We’re new here and excited to connect! Let’s make an impact together!✨🚀 #SciArt
drawimpacts.com
We’re new here and excited to connect! Let’s make an impact together!✨🚀 #SciArt
drawimpacts.com
Reposted by Hamza Celik
Download our database of 492 (!) funding opportunities for EARLY-CAREER FACULTY AND RESEARCHERS.
For each entry, we provide link to funder, description, amount, deadline, and eligibility criteria (e.g. citizenship).
Download freely here: research.jhu.edu/rdt/funding-...
For each entry, we provide link to funder, description, amount, deadline, and eligibility criteria (e.g. citizenship).
Download freely here: research.jhu.edu/rdt/funding-...
November 17, 2024 at 4:38 PM
Download our database of 492 (!) funding opportunities for EARLY-CAREER FACULTY AND RESEARCHERS.
For each entry, we provide link to funder, description, amount, deadline, and eligibility criteria (e.g. citizenship).
Download freely here: research.jhu.edu/rdt/funding-...
For each entry, we provide link to funder, description, amount, deadline, and eligibility criteria (e.g. citizenship).
Download freely here: research.jhu.edu/rdt/funding-...
Reposted by Hamza Celik
First manuscript from Linde Miles Lab at CCHMC looking at clonal evolution in NPM1-mut AML at single cell resolution. Check out the pre-print here: www.biorxiv.org/content/10.1...
Genotype-immunophenotype relationships in NPM1-mutant AML clonal evolution uncovered by single cell multiomic analysis
Acute myeloid leukemia (AML) is a multi-clonal disease, existing as a milieu of clones with unique but related genotypes as initiating clones acquire subsequent mutations. However, bulk sequencing can...
www.biorxiv.org
November 17, 2024 at 9:26 PM
First manuscript from Linde Miles Lab at CCHMC looking at clonal evolution in NPM1-mut AML at single cell resolution. Check out the pre-print here: www.biorxiv.org/content/10.1...
Reposted by Hamza Celik
Finally- the starter pack we have all been waiting for is here … Hematopoiesis 🎉❤️🩸🦴
So excited to have reached a critical mass of this community on here. 🙌🏻
Let me know if you want to be added!!
go.bsky.app/KWdX5w7
So excited to have reached a critical mass of this community on here. 🙌🏻
Let me know if you want to be added!!
go.bsky.app/KWdX5w7
November 17, 2024 at 8:22 AM
Finally- the starter pack we have all been waiting for is here … Hematopoiesis 🎉❤️🩸🦴
So excited to have reached a critical mass of this community on here. 🙌🏻
Let me know if you want to be added!!
go.bsky.app/KWdX5w7
So excited to have reached a critical mass of this community on here. 🙌🏻
Let me know if you want to be added!!
go.bsky.app/KWdX5w7
Reposted by Hamza Celik
It’s always a great start to the day to learn we have one more drug to offer patients with r/r leukemia! 🎗️🩸💊 www.fda.gov/drugs/resour...
FDA approves revumenib for relapsed or refractory acute leukemia
On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.
www.fda.gov
November 17, 2024 at 2:23 PM
It’s always a great start to the day to learn we have one more drug to offer patients with r/r leukemia! 🎗️🩸💊 www.fda.gov/drugs/resour...